AZBio Board Member Dr. Steve Potts discusses the negative impacts provisions of the Inflation Reduction Act (IRA) are having on the health innovation pipeline with Duane Schulthess, Managing Director of Vital Transformation, on the Vital Health Podcast.
Cancer
Drug Developer Dr. Steve Potts’ Congressional Testimony on the IRA
Featuring Dr. Steven J. Potts, PhD, MBA
Chair of the Drug Development Council, International Cancer Advocacy Network
In this Vital Health Podcast, we’re speaking with Steve Potts before his congressional testimony for the U.S. House Committee on Energy and Commerce. Steve presented evidence regarding the negative impacts of the Inflation Reduction Act on U.S. venture capital investors, the development of small molecules, and the needed therapies that will most likely be lost to patients over the next ten years.
Steve is a hugely successful serial entrepreneur in the life sciences, leading several companies to develop new cancer treatments. He is a board member of AZBio and an expert on the development of small molecules for the treatment of cancer.
About the Vital Health Podcast
Duane Schulthess, Managing Director of Vital Transformation, sits down for a relaxed, one on one discussion with health care professionals, researchers, and regulators. Duane and his guests will help you to better understand the implications of new medical procedures, technologies and policies and their impact on current clinical practices.
See all podcasts at https://vitaltransformation.com/podcasts/